Trading Statement

29 May 2015

Immunodiagnostic Systems Holdings plc

Trading Update

Immunodiagnostic Systems Holdings plc ("IDS", "the Company" or "the Group"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today provides a trading update for the year ended 31 March 2016.

The Board expects that for the current financial year to 31st March 2016 revenues will be in the range of £39-42 million. For the year ended 31 March 2015 revenues are expected to be £45 million in line with the guidance reconfirmed in April 2015. Final results for the year ended 31 March 2015 will be announced on 23 June 2015.

The Board remains committed to the continued execution of its strategic plan with the major objectives being 1) increased automated assay panel in its core endocrinology franchise by significantly increasing the rate of new product introductions; 2) implementing sales excellence to increase net new placements; 3) greater emphasis on cost management; and 4) M&A to accelerate the growth in automated IVDs. Further updates on these objectives will be provided in the final results announcement in June 2015.

For further information: